Aptose Biosciences Inc. (APTO)
NASDAQ: APTO · Real-Time Price · USD
0.279
+0.109 (63.92%)
At close: Dec 20, 2024, 4:00 PM
0.225
-0.054 (-19.35%)
After-hours: Dec 20, 2024, 7:59 PM EST
Aptose Biosciences Employees
As of December 31, 2023, Aptose Biosciences had 36 total employees, including 35 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
36
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$994,444
Market Cap
17.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Eyenovia | 57 |
Applied DNA Sciences | 55 |
Jaguar Health | 49 |
Apollomics | 45 |
Cellectar Biosciences | 20 |
Kiora Pharmaceuticals | 12 |
BioRestorative Therapies | 11 |
Can-Fite BioPharma | 8 |
APTO News
- 2 days ago - Aptose Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 9 days ago - Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax - GlobeNewsWire
- 12 days ago - Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - GlobeNewsWire
- 18 days ago - Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials - GlobeNewsWire
- 26 days ago - Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy - GlobeNewsWire
- 6 weeks ago - Aptose Reports Results for the Third Quarter 2024 - GlobeNewsWire